Publication at First Faculty of Medicine |
2012
Abstract
Incretin-based therapy represents currently preferred therapeutic option of type 2 diabetes mellitus owing to good efficacy, negligible side effects and potential cardio- and beta-cell-protective effects. The aim of this paper is to review current experience and knowledge concerning the use of vildagliptin in the treatment of diabetes.